Physician profile
Josepha M Simi
NPI 1861893729
$14,717.92
in general payments reported to CMS, 2019-2025
46 companies · $3,904 in 2025
The $3,904 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,925 · 2022: $1,909 · 2023: $2,619 · 2024: $4,360 · 2025: $3,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Honoraria: $500 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,269.19 |
| Honoraria | $500.00 |
| Education | $114.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,966.88 | 2021-2025 | |
| Pfizer INC. | $1,409.91 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $875.65 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lundbeck LLC | $872.39 | 2022-2025 | Vyepti |
| Tonix Medicines, INC. | $544.62 | 2024-2025 | Zembrace Symtouch |
| Biohaven Pharmaceuticals, INC. | $516.00 | 2021 | |
| Amgen INC. | $477.23 | 2021-2024 | Aimovig, Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $408.06 | 2022 | |
| Biogen, INC. | $331.31 | 2024-2025 | Vumerity, Tysabri, Qalsody |
| Novartis Pharmaceuticals Corporation | $308.16 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $305.93 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $293.40 | 2021-2025 | Reyvow, Emgality, Amyvid |
| Upsher-Smith Laboratories LLC | $246.97 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $162.90 | 2021-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $146.82 | 2023-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $143.97 | 2022-2025 | Zilbrysq, Briviact |
| Acadia Pharmaceuticals INC | $135.94 | 2021-2024 | Nuplazid |
| Argenx US, INC. | $122.07 | 2024-2025 | Vyvgart Hytrulo |
| Scilex Pharmaceuticals INC. | $121.78 | 2023-2024 | Ztlido |
| Novo Nordisk INC | $118.97 | 2025 | Wegovy |
| Incyte Corporation | $115.64 | 2024 | Opzelura |
| Merz Pharmaceuticals, LLC | $109.18 | 2024-2025 | Xeomin |
| Neurelis, INC. | $104.76 | 2024 | Valtoco |
| Mdd US Operations, LLC | $87.64 | 2024 | Gocovri |
| Allergan, INC. | $80.04 | 2021-2022 | |
| Csl Behring | $66.63 | 2022-2023 | Hizentra |
| Genentech USA, INC. | $64.17 | 2024 | Ocrevus |
| Impel Pharmaceuticals LLC | $62.11 | 2024-2025 | Trudhesa |
| Eisai INC. | $61.16 | 2024-2025 | |
| Kyowa Kirin, INC. | $58.48 | 2022-2023 | Nourianz |
| Emd Serono, INC. | $49.60 | 2024-2025 | |
| Impel Pharmaceuticals INC. | $43.68 | 2022-2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $30.71 | 2025 | Hyqvia |
| Supernus Pharmaceuticals, INC. | $29.29 | 2021 | |
| Amneal Pharmaceuticals LLC | $27.96 | 2023 | Rytary |
| Octapharma USA, INC. | $27.71 | 2022 | |
| Almatica Pharma LLC | $26.21 | 2021 | |
| Horizon Therapeutics Plc | $22.77 | 2021 | |
| Medtronic, INC. | $21.66 | 2021 | |
| Tanabe Pharma America, INC. | $19.33 | 2022 | |
| Grifols USA, LLC | $18.41 | 2023 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $18.19 | 2024 | Acthar |
| Averitas Pharma INC. | $17.98 | 2024 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $16.21 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.83 | 2022 | |
| Acorda Therapeutics, INC | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josepha Simi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.